The ATLAS Study is now enrolling adults who are carriers of certain SOD1 gene variants.
ALS = amyotrophic lateral sclerosis
If you think you may be a carrier of a certain superoxide dismutase 1 (SOD1) gene variant (also called a gene mutation) and you do not have any clinical signs or symptoms that definitively indicate onset of ALS, the ATLAS Study may offer you the opportunity to contribute to SOD1-ALS research.
Those who qualify will receive all study-related treatments and assessments, including genetic testing and counseling, at no cost. Reimbursement for study-related travel is available.
This clinical research study (also known as a clinical trial) is for adults who do not have any clinical signs or symptoms that definitively indicate onset of ALS but do carry a certain SOD1 gene variant that has high/complete penetrance and is associated with a rapidly progressive disease. Penetrance is the probability that individuals carrying a particular gene variant will actually develop the disease.1 Even if you don’t qualify for this study, Biogen may have an upcoming ALS clinical trial for which you may be eligible. If we determine you are not eligible for this study, you will still have the opportunity to add your name and contact information to our database at the end of this prescreening questionnaire so that you can be contacted for future studies.
If you are interested in taking part in this study, please continue below and complete the prescreening questionnaire to determine your eligibility.
Please note: For US residents only. For additional information on the ATLAS Study, please visit ClinicalTrials.gov.